Pricing Log in Create free account

Standard BioTools Inc. (LAB) vs RxSight, Inc. (RXST)

Standard BioTools Inc. and RxSight, Inc. are both Medical Devices companies. Standard BioTools Inc. is the larger, with a market value of $245.7M against $190.4M — 1.3× the size. RxSight, Inc. has negative trailing earnings, so its P/E is not meaningful; Standard BioTools Inc. trades at 1.8×. Standard BioTools Inc. grew revenue faster over the last twelve months: 35.3% against −14.3%. Standard BioTools Inc. has the higher net margin (157.6% vs −43.8%) and the higher return on invested capital (−54.2% vs −16,845.7%). Across the 19 metrics below, Standard BioTools Inc. leads on 11 and RxSight, Inc. on 8.

Valuation

Metric LAB RXST Medical Devices median
P/E 1.80 n/m 25.58
P/S 2.89 1.52 2.54
P/B 0.44 0.72 2.48
Price to free cash flow n/m 9.91 28.81
EV/EBITDA 2.63 0.77 11.51
EV/Sales (2.51) (0.41) 2.72
Earnings yield 55.53% (28.87%) (12.82%)
Free cash flow yield (29.61%) 10.09% (8.18%)

Profitability

Metric LAB RXST Medical Devices median
Gross margin 52.18% 76.13% 57.76%
Operating margin (97.47%) (50.44%) (15.07%)
Net margin 157.62% (43.80%) (14.45%)
Free cash flow margin (77.76%) 15.30% (3.88%)
Return on equity 27.86% (20.10%) (10.35%)
Return on assets 22.65% (16.44%) (17.26%)
Return on invested capital (54.18%) (16,845.67%) (5.27%)

Growth

Metric LAB RXST Medical Devices median
Revenue growth (TTM) 35.25% (14.26%) 10.41%
EPS growth (last fiscal year) 61.54% (33.80%) 28.17%
Revenue growth, 5-year CAGR (9.19%) 55.74% 15.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LAB RXST Medical Devices median
Debt to equity 0.00 0.00 0.04
Current ratio 9.75 4.20 2.74
Net debt to EBITDA 1.84 4.27 0.54

Dividend

Metric LAB RXST Medical Devices median
Dividend yield — — 1.02%
Payout ratio — — 0.37

Size

Metric LAB RXST Medical Devices median
Market cap 245.72m 190.36m 239.53m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack